{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Vatalanib_Succinate",
  "nciThesaurus": {
    "casRegistry": "212142-18-2",
    "chebiId": "",
    "chemicalFormula": "C20H15ClN4.C4H6O4",
    "definition": "The succinate salt of vatalanib, an anilinophthalazine derivative, with antineoplastic activity.  Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis.  This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.",
    "fdaUniiCode": "V5FUB77031",
    "identifier": "C74945",
    "preferredName": "Vatalanib Succinate",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C1742",
      "C1967"
    ],
    "synonyms": [
      "1-[4-Chloroanilino]-4-[4-pyridylmethyl]phthalazine Succinate",
      "Butanedioic Acid, Compd. with N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine (1:1)",
      "CGP 79787D",
      "PTK 787",
      "PTK-787",
      "PTK787",
      "VATALANIB SUCCINATE",
      "Vatalanib Succinate",
      "ZK 222584"
    ]
  }
}